The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Epidermolysis Bullosa Therapeutics Market Research Report 2024
Synopsis
The global Epidermolysis Bullosa Therapeutics market was valued at US$ 1626.4 million in 2023 and is anticipated to reach US$ 2268.2 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
North American market for Epidermolysis Bullosa Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Epidermolysis Bullosa Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Epidermolysis Bullosa Therapeutics include Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc. and Stratatech Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Epidermolysis Bullosa Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Epidermolysis Bullosa Therapeutics.
Report Scope
The Epidermolysis Bullosa Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Epidermolysis Bullosa Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Epidermolysis Bullosa Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline Plc
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd.
Segment by Type
EB-201
FCX-007
ICX-RHY
INM-750
Others
Segment by Application
Clinic
Hospital
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Epidermolysis Bullosa Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Epidermolysis Bullosa Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Epidermolysis Bullosa Therapeutics market was valued at US$ 1626.4 million in 2023 and is anticipated to reach US$ 2268.2 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
North American market for Epidermolysis Bullosa Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Epidermolysis Bullosa Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Epidermolysis Bullosa Therapeutics include Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc. and Stratatech Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Epidermolysis Bullosa Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Epidermolysis Bullosa Therapeutics.
Report Scope
The Epidermolysis Bullosa Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Epidermolysis Bullosa Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Epidermolysis Bullosa Therapeutics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Birken AG
Fibrocell Science, Inc.
GlaxoSmithKline Plc
InMed Pharmaceuticals Inc.
Karus Therapeutics Limited
ProQR Therapeutics N.V.
RegeneRx Biopharmaceuticals, Inc.
Scioderm, Inc.
Stratatech Corporation
TWi Pharmaceuticals, Inc.
WAVE Life Sciences Ltd.
Segment by Type
EB-201
FCX-007
ICX-RHY
INM-750
Others
Segment by Application
Clinic
Hospital
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Epidermolysis Bullosa Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Epidermolysis Bullosa Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Epidermolysis Bullosa Therapeutics Market Overview
1.1 Product Overview and Scope of Epidermolysis Bullosa Therapeutics
1.2 Epidermolysis Bullosa Therapeutics Segment by Type
1.2.1 Global Epidermolysis Bullosa Therapeutics Market Value Comparison by Type (2024-2030)
1.2.2 EB-201
1.2.3 FCX-007
1.2.4 ICX-RHY
1.2.5 INM-750
1.2.6 Others
1.3 Epidermolysis Bullosa Therapeutics Segment by Application
1.3.1 Global Epidermolysis Bullosa Therapeutics Market Value by Application: (2024-2030)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Epidermolysis Bullosa Therapeutics Market Size Estimates and Forecasts
1.4.1 Global Epidermolysis Bullosa Therapeutics Revenue 2019-2030
1.4.2 Global Epidermolysis Bullosa Therapeutics Sales 2019-2030
1.4.3 Global Epidermolysis Bullosa Therapeutics Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Epidermolysis Bullosa Therapeutics Market Competition by Manufacturers
2.1 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Manufacturers (2019-2024)
2.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Epidermolysis Bullosa Therapeutics Average Price by Manufacturers (2019-2024)
2.4 Global Epidermolysis Bullosa Therapeutics Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Product Type & Application
2.7 Epidermolysis Bullosa Therapeutics Market Competitive Situation and Trends
2.7.1 Epidermolysis Bullosa Therapeutics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Epidermolysis Bullosa Therapeutics Players Market Share by Revenue
2.7.3 Global Epidermolysis Bullosa Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Epidermolysis Bullosa Therapeutics Retrospective Market Scenario by Region
3.1 Global Epidermolysis Bullosa Therapeutics Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Epidermolysis Bullosa Therapeutics Global Epidermolysis Bullosa Therapeutics Sales by Region: 2019-2030
3.2.1 Global Epidermolysis Bullosa Therapeutics Sales by Region: 2019-2024
3.2.2 Global Epidermolysis Bullosa Therapeutics Sales by Region: 2025-2030
3.3 Global Epidermolysis Bullosa Therapeutics Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2019-2030
3.3.1 Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2019-2024
3.3.2 Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2025-2030
3.4 North America Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
3.4.1 North America Epidermolysis Bullosa Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Epidermolysis Bullosa Therapeutics Sales by Country (2019-2030)
3.4.3 North America Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
3.5.1 Europe Epidermolysis Bullosa Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Epidermolysis Bullosa Therapeutics Sales by Country (2019-2030)
3.5.3 Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
3.6.1 Asia Pacific Epidermolysis Bullosa Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Epidermolysis Bullosa Therapeutics Sales by Country (2019-2030)
3.6.3 Asia Pacific Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
3.7.1 Latin America Epidermolysis Bullosa Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Epidermolysis Bullosa Therapeutics Sales by Country (2019-2030)
3.7.3 Latin America Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country
3.8.1 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Epidermolysis Bullosa Therapeutics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Epidermolysis Bullosa Therapeutics Sales by Type (2019-2030)
4.1.1 Global Epidermolysis Bullosa Therapeutics Sales by Type (2019-2024)
4.1.2 Global Epidermolysis Bullosa Therapeutics Sales by Type (2025-2030)
4.1.3 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2019-2030)
4.2 Global Epidermolysis Bullosa Therapeutics Revenue by Type (2019-2030)
4.2.1 Global Epidermolysis Bullosa Therapeutics Revenue by Type (2019-2024)
4.2.2 Global Epidermolysis Bullosa Therapeutics Revenue by Type (2025-2030)
4.2.3 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2019-2030)
4.3 Global Epidermolysis Bullosa Therapeutics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Epidermolysis Bullosa Therapeutics Sales by Application (2019-2030)
5.1.1 Global Epidermolysis Bullosa Therapeutics Sales by Application (2019-2024)
5.1.2 Global Epidermolysis Bullosa Therapeutics Sales by Application (2025-2030)
5.1.3 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2019-2030)
5.2 Global Epidermolysis Bullosa Therapeutics Revenue by Application (2019-2030)
5.2.1 Global Epidermolysis Bullosa Therapeutics Revenue by Application (2019-2024)
5.2.2 Global Epidermolysis Bullosa Therapeutics Revenue by Application (2025-2030)
5.2.3 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2019-2030)
5.3 Global Epidermolysis Bullosa Therapeutics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Birken AG
6.1.1 Birken AG Corporation Information
6.1.2 Birken AG Description and Business Overview
6.1.3 Birken AG Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Birken AG Epidermolysis Bullosa Therapeutics Product Portfolio
6.1.5 Birken AG Recent Developments/Updates
6.2 Fibrocell Science, Inc.
6.2.1 Fibrocell Science, Inc. Corporation Information
6.2.2 Fibrocell Science, Inc. Description and Business Overview
6.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.2.5 Fibrocell Science, Inc. Recent Developments/Updates
6.3 GlaxoSmithKline Plc
6.3.1 GlaxoSmithKline Plc Corporation Information
6.3.2 GlaxoSmithKline Plc Description and Business Overview
6.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product Portfolio
6.3.5 GlaxoSmithKline Plc Recent Developments/Updates
6.4 InMed Pharmaceuticals Inc.
6.4.1 InMed Pharmaceuticals Inc. Corporation Information
6.4.2 InMed Pharmaceuticals Inc. Description and Business Overview
6.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.4.5 InMed Pharmaceuticals Inc. Recent Developments/Updates
6.5 Karus Therapeutics Limited
6.5.1 Karus Therapeutics Limited Corporation Information
6.5.2 Karus Therapeutics Limited Description and Business Overview
6.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product Portfolio
6.5.5 Karus Therapeutics Limited Recent Developments/Updates
6.6 ProQR Therapeutics N.V.
6.6.1 ProQR Therapeutics N.V. Corporation Information
6.6.2 ProQR Therapeutics N.V. Description and Business Overview
6.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product Portfolio
6.6.5 ProQR Therapeutics N.V. Recent Developments/Updates
6.7 RegeneRx Biopharmaceuticals, Inc.
6.6.1 RegeneRx Biopharmaceuticals, Inc. Corporation Information
6.6.2 RegeneRx Biopharmaceuticals, Inc. Description and Business Overview
6.6.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.7.5 RegeneRx Biopharmaceuticals, Inc. Recent Developments/Updates
6.8 Scioderm, Inc.
6.8.1 Scioderm, Inc. Corporation Information
6.8.2 Scioderm, Inc. Description and Business Overview
6.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.8.5 Scioderm, Inc. Recent Developments/Updates
6.9 Stratatech Corporation
6.9.1 Stratatech Corporation Corporation Information
6.9.2 Stratatech Corporation Description and Business Overview
6.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Stratatech Corporation Epidermolysis Bullosa Therapeutics Product Portfolio
6.9.5 Stratatech Corporation Recent Developments/Updates
6.10 TWi Pharmaceuticals, Inc.
6.10.1 TWi Pharmaceuticals, Inc. Corporation Information
6.10.2 TWi Pharmaceuticals, Inc. Description and Business Overview
6.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.10.4 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio
6.10.5 TWi Pharmaceuticals, Inc. Recent Developments/Updates
6.11 WAVE Life Sciences Ltd.
6.11.1 WAVE Life Sciences Ltd. Corporation Information
6.11.2 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Description and Business Overview
6.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2019-2024)
6.11.4 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product Portfolio
6.11.5 WAVE Life Sciences Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Epidermolysis Bullosa Therapeutics Industry Chain Analysis
7.2 Epidermolysis Bullosa Therapeutics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Epidermolysis Bullosa Therapeutics Production Mode & Process
7.4 Epidermolysis Bullosa Therapeutics Sales and Marketing
7.4.1 Epidermolysis Bullosa Therapeutics Sales Channels
7.4.2 Epidermolysis Bullosa Therapeutics Distributors
7.5 Epidermolysis Bullosa Therapeutics Customers
8 Epidermolysis Bullosa Therapeutics Market Dynamics
8.1 Epidermolysis Bullosa Therapeutics Industry Trends
8.2 Epidermolysis Bullosa Therapeutics Market Drivers
8.3 Epidermolysis Bullosa Therapeutics Market Challenges
8.4 Epidermolysis Bullosa Therapeutics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
